We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01579500
First Posted: April 18, 2012
Last Update Posted: April 25, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Health Insurance Service Ilsan Hospital
Medy-Tox
Information provided by (Responsible Party):
Myung Eun, Chung, Catholic University of Korea Saint Paul's Hospital
  Purpose
The purpose of this study is to determine whether botulinum toxin A is effective in the treatment of neuropathic pain in spinal cord injury patients.

Condition Intervention Phase
Spinal Cord Injury Neuropathic Pain Drug: Botulinum toxin type A Drug: normal saline Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Botulinum Toxin A in Post Spinal Cord Injury Neuropathic Pain

Resource links provided by NLM:


Further study details as provided by Myung Eun, Chung, Catholic University of Korea Saint Paul's Hospital:

Primary Outcome Measures:
  • Visual analogue scale [ Time Frame: 4 weeks after intervention ]

Enrollment: 40
Study Start Date: April 2012
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: botulinum toxin A Drug: Botulinum toxin type A
Subcutaneous injection of botulinum toxin type A
Placebo Comparator: normal saline Drug: normal saline
Subcutaneous injection of normal saline

Detailed Description:
Neuropathic pain remains a significant cause of life quality deterioration. This study includes spinal cord injury patients with refractory chronic neuropathic pain and investigates whether injection with botulinum toxin A improves pain scores.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • more than twenty years of age
  • paraplegic or tetraplegic due to cervical and thoracic spinal cord injury
  • more than 12 months since spinal cord injury and ASIA impairment scale unchanged for more than 6 months
  • persistence of neuropathic pain for more than three months or remission and recurrence of neuropathic pain for more than six months
  • a pain score of 40mm or more on the visual analogue scale

Exclusion Criteria:

  • neuropathic pain caused by confounding factors other than spinal cord injury
  • contraindicated for botulinum toxin type A
  • a change in pain medication one month prior to study enrollment
  • a condition involving neuromuscular junction (Ex. Eaton Lambert disease, myasthenia gravis)
  • person who received botulinum toxin type A within three months prior to study enrollment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01579500


Locations
Korea, Republic of
Catholic University Saint Paul's Hospital; National Health Insurance Corporation Ilsan Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Catholic University of Korea Saint Paul's Hospital
National Health Insurance Service Ilsan Hospital
Medy-Tox
  More Information

Responsible Party: Myung Eun, Chung, clinical assistant proffessor, Catholic University of Korea Saint Paul's Hospital
ClinicalTrials.gov Identifier: NCT01579500     History of Changes
Other Study ID Numbers: PC12MIMV0005
20120007154 ( Other Identifier: Korea food and drug administration )
suyon 2011-131 ( Other Identifier: National Health Insurance Corporation Ilsan Hospital institutional review board )
First Submitted: April 16, 2012
First Posted: April 18, 2012
Last Update Posted: April 25, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Wounds and Injuries
Spinal Cord Injuries
Neuralgia
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Pain
Neurologic Manifestations
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Botulinum Toxins
Botulinum Toxins, Type A
onabotulinumtoxinA
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents